NPI 1013929470: Open Payments
NPI 1013929470. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,582 in 185 payments from 18 companies in 2025. Trend: 2023 $4,592 · 2024 $5,939 · 2025 $3,582
Food & beverage: $3,570Education: $11
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 20 | $463 |
| ABBVIE INC. | 20 | $386 |
| Lundbeck LLC | 21 | $367 |
| Alkermes, Inc. | 25 | $344 |
| Neurocrine BioSciences, Inc. | 10 | $289 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $252 |
| Vanda Pharmaceuticals Inc. | 8 | $216 |
| Supernus Pharmaceuticals, Inc. | 19 | $208 |
| Teva Pharmaceuticals USA, Inc. | 9 | $192 |
| E.R. Squibb & Sons, L.L.C. | 9 | $191 |
Products named: Auvelity, VRAYLAR, ARISTADA, INGREZZA, CAPLYTA, FANAPT, Qelbree, REXULTI.
